| abstract |
The invention relates to monoclonal antibodies (MAbs) against the human immunodeficiency virus (HIV) allowing the neutralization of HIV and / or an antibody-dependent cytotoxicity with respect to cells infected with the virus, as well as a process for the preparation of these MAbs and of hybridomas producing these MAbs. These MAbs serve, among other things, as a passive or active vaccine, as well as for the prevention of the spread of HIV infections, for the analysis of HIV antigens and for the identification of a neutralization epitope in preparations intended for immunization. |